Yedida Y Bogachkov PhD,  —

Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. She’s a Chicago native and hasn’t moved out of her hometown. Yes, she actually likes snow and enjoys having all four seasons. Yedida likes being out in nature, and in her free time, she can be found outside enjoying the fresh air or baking (inside). She is, unsuccessfully, trying to persuade the rest of her family to enjoy hiking. Yedida is excited to bring her passion for science and her desire to help people to BioNews.

Articles by Yedida Y Bogachkov PhD

Untreated IPF Linked to 50% Mortality Rate at 3 Years

If left untreated by anti-fibrotic medications, idiopathic pulmonary fibrosis (IPF) has a 50% mortality rate after three years, according to a recent observational study using real-world data. This is compared with a 26–31% mortality rate among IPF patients taking available anti-fibrotics, such as Esbriet (pirfenidone) and Ofev…

AstraZeneca, BenevolentAI Identify New Treatment Target

AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF) to its portfolio, which was uncovered using BenevolentAI’s artificial intelligence-driven medication discovery platform. “The cause of IPF is largely unknown and the exact mechanisms involved in the progression of IPF remain elusive,” Anne Phelan, PhD, chief scientific…

Potential IPF Treatment AD-214 Works in Inhaled Form, AdAlta Says

AdAlta announced that AD-214, its candidate treatment for idiopathic pulmonary fibrosis (IPF), has been successfully made into an aerosol for inhalation — a nebulized form — while retaining the molecular properties that supported its potential effectiveness in preclinical studies. “The results of these studies support AD-214 being delivered by…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums